April 22, 2025CorporateTerumo unveils “Terumo Group Statement on Nature,” a guideline for its actions on conservation and restoration of natural environments
April 16, 2025CorporateTerumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth
April 16, 2025CorporateTerumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort –
The Latest Materials 3rd Quarter Financial Results for FYE 3/2025 February 13, 2025 Financial Statements IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (PDF 248.94 KB) Presentation Material Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 543.7 KB) Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 312.9 KB) Additional Information Revenue by Segment (PDF 291.85 KB) Revenue by Segment (Excel 228.14 KB) Q&A Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 237.28 KB) Webcast Listen to the Webcast Financial Statements /investors/library/financial-statements Presentations /investors/library/presentations Terumo Report /investors/library/annual-reports Sustainability /sustainability Corporate Governance /about/governance Consolidated Financial Statements /investors/library/financial Adobe Reader is required for viewing PDF files. Download Adobe Reader
IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (PDF 248.94 KB)
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 312.9 KB)
Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 237.28 KB)